- PGLA Stock Page
Progen Pharmaceuticals Limited (NASDAQCM:PGLA)
Last Update: Yesterday at 3:00 ET
| Change: | -0.01 (-1.70%) |
| Last Trade: | 0.58 |
| Prev Close: | 0.59 |
| Share Volume: | 7,800 |
| Market Cap: | 35.06M |
| EPS (Earnings per share): | -0.37 |
| P/E (Price/earning ratio): | N/A |
| P/B (Price/book ratio): | 0.42 |
| Stock Price History | |
|---|---|
| Beta: | 0.51 |
| 52 week change: | -81.50% |
| 52 week high: | 3.32 |
| 52 week low: | 0.39 |
| 10 day moving avarage: | 0.58 |
| 200 day moving avarage: | 1.45 |
| Dividends | |
| Ex dividend date: | N/A |
| Dividend yield: | N/A |
| Dividend rate: | N/A |
| Share Statistics | |
| Avarage 10 day volume: | 13,500 |
| Shares outstanding: | 59,416,427 |
| Short interest date: | Aug 12, 2008 |
| Short shares: | 894 |
| Short ratio: | N/A |
| Short % of float: | N/A |
Fri, 5 Sep 2008 3:00 PM
After-Hours:
0.55
-0.03 (-5.17%)
| Today | 5d | 1m | 3m | 6m | 1y | 5y |
Latest News for PGLA
-
PR Newswire
- Jul 22 at 7:35 ET
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
Company Profile
Sector: Healthcare
Industry: Drugs
globally-focused biotechnology products.
A biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics for the treatment of cancer and other serious diseases.
PGLA News
-
PR Newswire
- Jul 22 at 7:35 ET
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A -
EDGAR Online Financials
- Dec 22 2007 at 9:04 ET
PROGEN PHARMACEUTICALS LTD Financials